Merck 4Q Revenues: $15.6 billion (+7%) 4Q Earnings: $3.7 billion (loss of $1.2 billion 4Q23) FY Revenues: $64.2 billion (+7%) FY Earnings: $17.1 billion (earnings were $365 million FY23) Comments: Keytruda sales were $7.8 billion in the quarter, up 19%, driven by continued global demand from metastatic indications, including increased uptake in bladder and endometrial cancers, as well as increased global uptake in earlier-stage indications, including triple-negative breast cancer ...